Abstract: A seat back panel includes a panel main body and a separate panel. The panel main body is disposed at a posterior portion of a seat back of a vehicle seat. The panel main body structures a portion of a main body portion of a seat back frame. An aperture is formed at a location of the panel main body that opposes a dorsal region of a seat occupant. The separate panel is attached to the main body portion and closes up the aperture. At a time of rear-end collision of the vehicle, the separate panel receives a load from the dorsal region of the seat occupant and relatively displaces toward the rear side of the seat back with respect to the panel main body.

Abstract: Desired is development of novel CDN derivatives having STING agonist activity; and a therapeutic agents and/or therapeutic methods using the novel CDN derivatives for diseases associated with STING agonist activity. Further desired is development of a therapeutic agents and/or therapeutic methods capable of delivering the novel CDN derivatives specifically to targeted cells and organs for diseases associated with STING agonist activity. The present invention provides novel CDN derivatives having potent STING agonist activity, and antibody-CDN derivative conjugates including the novel CDN derivatives.

Abstract: It is intended to provide a method for determining a tumor. The method for determining a tumor comprises: (1) treating genomic DNA prepared from a subject tissue or cell with bisulfite (the subject tissue or cell is derived from a patient who is affected by a tumor and is determined as (i) having MSI-H of the tumor in MSI examination and/or no or reduced expression of MLH1 in the tumor in immunohistochemical examination, and (ii) having no mutation in MLH1 in genetic examination); 2) amplifying, by PCR, DNA comprising a portion or the whole of MLH1 promoter region from the bisulfite-treated DNA; 3) subjecting the PCR amplification product to ion exchange chromatography to obtain a detection signal; 4) determining whether or not the peak of the detection signal is a peak indicating highly methylated DNA; and 5) determining the tumor as a tumor derived from a patient without Lynch syndrome when the peak is determined as a peak indicating highly methylated DNA.

Abstract: It is intended to provide a method for determining a tumor. The method for determining a tumor comprises: (1) treating genomic DNA prepared from a subject tissue or cell with bisulfite (the subject tissue or cell is derived from a patient who is affected by a tumor and is determined as (i) having MSI-H of the tumor in MSI examination and/or no or reduced expression of MLH1 in the tumor in immunohistochemical examination, and (ii) having no mutation in MLH1 in genetic examination); 2) amplifying, by PCR, DNA comprising a portion or the whole of MLH1 promoter region from the bisulfite-treated DNA; 3) subjecting the PCR amplification product to ion exchange chromatography to obtain a detection signal; 4) determining whether or not the peak of the detection signal is a peak indicating highly methylated DNA; and 5) determining the tumor as a tumor derived from a patient without Lynch syndrome when the peak is determined as a peak indicating highly methylated DNA.

Abstract: A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, hyper-LDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group, and R1 is a hydrogen atom or a hydroxy group.

Abstract: A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, hyper-LDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group, and R1 is a hydrogen atom or a hydroxy group.

Abstract: A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group.

Abstract: A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group.

Abstract: Provided are a decorative sheet which is enhanced in durability of an edge portion of a soft feel layer thereof and which is unlikely to suffer breakage, a method of manufacturing such a decorative sheet, a decorative molded body, and a decorative key sheet. A compressed portion formed by crushing a foam layer in a thickness direction is provided at a side surface of an edge portion of a decorative sheet with a soft touch feeling.

Abstract: The present invention provides a technique that can divide and illuminate display elements juxtaposed in one key top for each use function. Areas divided by the dividing portions of the attenuation means in the projection surface of the key top can be respectively illuminated by backlights from different LEDs, so each divided area can be individually controlled and illuminated. Therefore, it is possible to realize a key sheet in which display elements juxtaposed in one key top are divided for each use function and illuminated.

Abstract: Provided is a key sheet which has a soft touch feeling and in which elaborate and highly visible display portions can be provided. In a key sheet including: a translucent base sheet; and a soft-feel layer which is laminated on a front surface side of the base sheet, includes a plurality of display portions representing key types such as letters, numerals, and symbols, and has a soft touch feeling, the soft-feel layer includes a translucent skin layer having the soft touch feeling and decorative portions which are provided on a back surface of the skin layer and are visible through the skin layer. Further, light emitted from an inside of a device transmits through the base sheet so as to reach the decorative portions, and hence it is possible to obtain an illumination-type key sheet excellent in illumination property and of wider variety.

Abstract: Provided are a decorative sheet which is enhanced in durability of an edge portion of a soft feel layer thereof and which is unlikely to suffer breakage, a method of manufacturing such a decorative sheet, a decorative molded body, and a decorative key sheet. A compressed portion formed by crushing a foam layer in a thickness direction is provided at a side surface of an edge portion of a decorative sheet with a soft touch feeling.

Abstract: To provide a decorative sheet having enhanced durability of an edge portion of a soft feel layer and is unlikely damaged, a manufacturing method for a decorative sheet, a decorative molded body, and a decorative key sheet, a decorative sheet with a soft touch feeling has a foamed layer having a side surface of an edge portion

Abstract: Provided are a pointing device allowing accurate depressing operation on a key top and involving no erroneous input or erroneous operation, and a key sheet for the pointing device. On the back surface of a base sheet (14) of a key sheet (15) for a pointing device, an accommodating portion (17) for a magnet (13), for accommodating portion greatly protrudes toward a board (P) beyond a pusher (14b) is provided. When the key top (12) is depressed, the accommodating portion (17) and the magnet (13) come into contact with the board (P), and causes the depressed key top (12) to tilt using the point of contact as a fulcrum, thereby pressing the pusher (14b) against a contact switch (Pi, Po). Thus, it is possible to reduce the thickness and weight of the pointing device (10) and the key sheet (15) for the pointing device. Further, a reduction is achieved in terms of the possibility of erroneous input and erroneous operation, making it possible to reliably effect confirmation input.

Abstract: Provided are a pointing device allowing accurate depressing operation on a key top and involving no erroneous input or erroneous operation, and a key sheet for the pointing device. On the back surface of a base sheet (14) of a key sheet (15) for a pointing device, an accommodating portion (17) for a magnet (13), for accommodating portion greatly protrudes toward a board (P) beyond a pusher (14b) is provided. When the key top (12) is depressed, the accommodating portion (17) and the magnet (13) come into contact with the board (P), and causes the depressed key top (12) to tilt using the point of contact as a fulcrum, thereby pressing the pusher (14b) against a contact switch (Pi, Po). Thus, it is possible to reduce the thickness and weight of the pointing device (10) and the key sheet (15) for the pointing device. Further, a reduction is achieved in terms of the possibility of erroneous input and erroneous operation, making it possible to reliably effect confirmation input.

Abstract: A DC power supply apparatus for supplying a DC power to a plasma generating device, includes: an input section for converting an inputted AC power into a DC power; a current type of inverter connected with a next stage of the input section; a transformer having a primary winding and a secondary winding, the primary winding being connected with the current type of inverter; a rectifying section for rectifying an AC power generated in the secondary winding of the transformer; and a smoothing circuit for smoothing the rectified power which is rectified by the rectifying section; wherein an electric energy to be supplied to the plasma generating device is controlled by controlling a switching operation of the current type of inverter as a current source.

Abstract: A DC power supply apparatus for supplying a DC power to a plasma generating device, includes: an input section for converting an inputted AC power into a DC power; a current type of inverter connected with a next stage of the input section; a transformer having a primary winding and a secondary winding, the primary winding being connected with the current type of inverter; a rectifying section for rectifying an AC power generated in the secondary winding of the transformer; and a smoothing circuit for smoothing the rectified power which is rectified by the rectifying section; wherein an electric energy to be supplied to the plasma generating device is controlled by controlling a switching operation of the current type of inverter as a current source.

Abstract: Compounds of formula (I) or their salts or esters: have excellent sialidase inhibitory activity and are therefore useful for the treatment and prevention of influenza and other viral diseases where the replication of the virus is susceptible to sialidase inhibitors.

Abstract: Compounds of formula (I): ##STR1## in which: R.sup.1 is hydroxy, protected hydroxy, fluorine, or --OP(O)(OH).sub.2 ; R.sup.2 and R.sup.3 are independently optionally substituted C.sub.6 -C.sub.20 aliphatic acyl; R.sup.4 is hydroxy, protected hydroxy, or --OP(O)(OH).sub.2, where at least one of R.sup.1 and R.sup.4 is --OP(O)(OH).sub.2 ; and R.sup.5 is hydroxy, protected hydroxy, or fluorine; provided that, except where at least one of R.sup.1 and R.sup.5 is fluorine, then at least one of R.sup.2 and R.sup.3 is a substituted C.sub.6 -C.sub.20 aliphatic acyl having (i) at least one halogen substituent and (ii) at least one substituent selected from the group consisting of halogen, hydroxy and C.sub.6 -C.sub.20 aliphatic acyloxy or at least one of R.sup.2 and R.sup.3 is a substituted C.sub.6 -C.sub.20 aliphatic acyl which is substituted by at least one halogen-substituted C.sub.6 -C.sub.

Abstract: In a wireless communication apparatus arranged by an indoor unit, an outdoor unit, and a cable used to connect the indoor unit with the outdoor unit, a gain of an amplifier is automatically set. This amplifier amplifies a lowered level of a signal caused by a cable loss. To perform such an automatic gain setting operation, a cable loss equalization system is used in this wireless communication apparatus. The cable loss equalization system compensates for a reduction in a level of a main signal caused by the cable.